The accumulation of acylcarnitine in obesity- and NASH-related HCC tissues has been attributed to downregulation of CPT2, which is also observed in human NAFLD-related HCC tissues. Here, CPT2 is linked to metabolic dysfunction-associated steatotic liver disease.